Acerus Pharmaceuticals Corporation announced the launch of a dedicated sales team to promote the Company’s key product, NATESTO® (testosterone nasal gel), to urologists and endocrinologists across the United States. The 22 specialty sales representatives will target high-prescribing (decile 6-10) medical practitioners who currently treat men with hypogonadism. Acerus, in partnership with Syneos Health, has equipped its U.S. team with a suite of digital technologies that will allow reps to conduct virtual meetings and customer engagements, given varying state rules regarding COVID-19 restrictions. In addition, as per the terms of the revised partnership agreement between Acerus and Aytu BioScience, Aytu will focus their own U.S. sales team (currently comprised of some 33 representatives) on the promotion of NATESTO® to high-prescribing primary care physicians who treat men with hypogonadism. The launch of the Acerus Specialty Sales team in the United States is a significant milestone in the commercialization of NATESTO®.